Stem definition | Drug id | CAS RN |
---|---|---|
4301 | 765922-62-1 |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 25, 2013 | FDA | GE HEALTHCARE |
None
Source | Code | Description |
---|---|---|
ATC | V09AX04 | VARIOUS DIAGNOSTIC RADIOPHARMACEUTICALS CENTRAL NERVOUS SYSTEM Other central nervous system diagnostic radiopharmaceuticals |
FDA EPC | N0000177914 | Radioactive Diagnostic Agent |
FDA MoA | N0000000205 | Radiopharmaceutical Activity |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Positron emission tomography | indication | 82918005 |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
121.5mCi/30ML (4.05mCi/ML) | VIZAMYL | GE HEALTHCARE | N203137 | Oct. 25, 2013 | RX | INJECTABLE | INTRAVENOUS | 7351401 | Jan. 24, 2023 | DIAGNOSTIC RADIOIMAGING |
121.5mCi/30ML (4.05mCi/ML) | VIZAMYL | GE HEALTHCARE | N203137 | Oct. 25, 2013 | RX | INJECTABLE | INTRAVENOUS | 8691185 | Jan. 24, 2023 | DIAGNOSTIC RADIOIMAGING |
40.5mCi/10ML (4.05mCi/ML) | VIZAMYL | GE HEALTHCARE | N203137 | Oct. 25, 2013 | RX | INJECTABLE | INTRAVENOUS | 7351401 | Jan. 24, 2023 | DIAGNOSTIC RADIOIMAGING |
40.5mCi/10ML (4.05mCi/ML) | VIZAMYL | GE HEALTHCARE | N203137 | Oct. 25, 2013 | RX | INJECTABLE | INTRAVENOUS | 8691185 | Jan. 24, 2023 | DIAGNOSTIC RADIOIMAGING |
121.5mCi/30ML (4.05mCi/ML) | VIZAMYL | GE HEALTHCARE | N203137 | Oct. 25, 2013 | RX | INJECTABLE | INTRAVENOUS | 7270800 | Sept. 3, 2025 | DIAGNOSTIC RADIOIMAGING |
40.5mCi/10ML (4.05mCi/ML) | VIZAMYL | GE HEALTHCARE | N203137 | Oct. 25, 2013 | RX | INJECTABLE | INTRAVENOUS | 7270800 | Sept. 3, 2025 | DIAGNOSTIC RADIOIMAGING |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
121.5mCi/30ML (4.05mCi/ML) | VIZAMYL | GE HEALTHCARE | N203137 | Oct. 25, 2013 | RX | INJECTABLE | INTRAVENOUS | Oct. 25, 2018 | NEW CHEMICAL ENTITY |
40.5mCi/10ML (4.05mCi/ML) | VIZAMYL | GE HEALTHCARE | N203137 | Oct. 25, 2013 | RX | INJECTABLE | INTRAVENOUS | Oct. 25, 2018 | NEW CHEMICAL ENTITY |
None
ID | Source |
---|---|
C2983948 | UMLSCUI |
7342 | IUPHAR_LIGAND_ID |
D10231 | KEGG_DRUG |
DB09151 | DRUGBANK_ID |
CHEMBL2042122 | ChEMBL_ID |
456996004 | SNOMEDCT_US |
456997008 | SNOMEDCT_US |
29778 | MMSL |
d08135 | MMSL |
1486025 | RXNORM |
016452 | NDDF |
15950376 | PUBCHEM_CID |
L49M066S0O | UNII |
C581552 | MESH_SUPPLEMENTAL_RECORD_UI |
CHEBI:76611 | CHEBI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Vizamyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17156-067 | SOLUTION | 4.05 mCi | INTRAVENOUS | NDA | 16 sections |